Preview Mode Links will not work in preview mode

Jul 14, 2020

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Liu on the following topics:

  • Molecular profiling and genetic counseling for patients with newly diagnosed OC (00:00)
  • FDA approval and optimal use of niraparib or olaparib/bevacizumab as front-line maintenance therapy for patients with advanced OC (6:17)
  • Perspective on the benefit with bevacizumab and a PARP inhibitor for patients with OC (9:51)

CME information and select publications